Market Research Report
Nebulizer Market Size, Share & Trends Analysis Report By Type (Jet, Mesh, Ultrasonic), By End-use (Hospitals & Clinics, Emergency Centers & Home Healthcare), And Segment Forecasts, 2019 - 2026
|Published by||Grand View Research, Inc.||Product code||615517|
|Published||Content info||110 Pages
Delivery time: 2-3 business days
|Nebulizer Market Size, Share & Trends Analysis Report By Type (Jet, Mesh, Ultrasonic), By End-use (Hospitals & Clinics, Emergency Centers & Home Healthcare), And Segment Forecasts, 2019 - 2026|
|Published: August 13, 2019||Content info: 110 Pages||
The global nebulizer market size is expected to reach USD 1.4 billion by 2026, according to a new report by Grand View Research, Inc., expanding at a CAGR of 6.5% over the forecast period. Rising incidence rate of chronic respiratory diseases, increasing demand for home healthcare devices, and rising geriatric population worldwide are the major factors leading to the market growth.
According to the Population Reference Bureau report, "Aging in the United States", the geriatric population in U.S. is estimated to increase from 48 million in 2016 to 98 million by 2060. Elderly people are susceptible to respiratory diseases such as COPD and sleep apnea. Therefore, growing geriatric population is expected to expand the patient pool for manufacturers and propel the growth of the market.
On the other hand, drug loss during nebulization is the major factor restraining the market growth. However, this can also act as an opportunity for the mesh nebulizer manufacturers as the devices are manufactured to deliver accurate drug dosage while reduce drug loss. Furthermore, increasing commercial acceptance of mesh nebulizers due to accurate delivery of drug to the lung and lower residual volumes also aids in market growth.
Technological advancements such as drug-device combination is further expected to create newer opportunity in the nebulizer market. The key manufacturers are expected to dominate the market of drug device combinations till the generic mesh nebulizer manufacturers invest in the support infrastructure required for development of the new pharmaceuticals. For instance; In 2016, Sunovion filed the first application for the approval of SUN-101. A mesh nebulizer in combination with a drug for COPD (SUN-101) will be a significant step for boosting the adoption of nebulizers. Other companies such as Vectura also have products in late stage development, e.g., VR475, indicated for severe asthma, in Phase III trials.
Key players include: Omron Corporation, Koninklijke Philips N.V., PARI Pharma, Allied Healthcare Products, Inc., Becton Dickinson and Company, Agilent Technologies, Medline Industries, Briggs Healthcare, Drive Medical and GF Health Products, Inc.